Diffuse large B‑cell lymphoma in the new era: prognostic tools for mapping risk
CAR T‑cell therapy should be considered early—within 12 months of relapse—for patients with diffuse large B‑cell lymphoma, as phase‑13 trials demonstrate superior overall survival, improved event‑free survival, and lower neurotoxicity compared with standard therapy.
Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Related signals
- Diffuse Large B‑Cell Lymphoma – Global Clinical Trial Landscape (2024)
- Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
- Mantle‑Cell Lymphoma (MCL)
- Inhibition of autoantigen‑induced B‑cell receptor (BCR) internalization as a therapeutic strategy in diffuse large B cell lymphoma (DLBCL)
- Successful treatment of primary refractory DLBCL/HGBL - MYC/BCL2 transformed from FL using glofitamab: a case report